Cargando…

Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review

With the widespreading use of biologic drugs, reports of renal injury are increasing, most of which belong to the spectrum of secondary autoimmune syndromes. We present the case of a young man affected by Ankylosing Spondylitis, treated with tumor necrosis factor alpha inhibitors (Anti-TNF) that dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Diena, Davide, Priora, Marta, Barreca, Antonella, Parisi, Simone, Colla, Loredana, Biancone, Luigi, Fusaro, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683916/
https://www.ncbi.nlm.nih.gov/pubmed/33281463
http://dx.doi.org/10.1177/1179547620974672
_version_ 1783612978825789440
author Diena, Davide
Priora, Marta
Barreca, Antonella
Parisi, Simone
Colla, Loredana
Biancone, Luigi
Fusaro, Enrico
author_facet Diena, Davide
Priora, Marta
Barreca, Antonella
Parisi, Simone
Colla, Loredana
Biancone, Luigi
Fusaro, Enrico
author_sort Diena, Davide
collection PubMed
description With the widespreading use of biologic drugs, reports of renal injury are increasing, most of which belong to the spectrum of secondary autoimmune syndromes. We present the case of a young man affected by Ankylosing Spondylitis, treated with tumor necrosis factor alpha inhibitors (Anti-TNF) that develop a peculiar renal damage: a coexistence of 2 glomerulonephritis due to different noxae, an IgA nephropaty with a Membranous nephropathy. The first one probably related to the rheumatologic disease, the second one related to Anti-TNF. Despite the underlying mechanisms, the renal involvement both related to Ankylosing Spondylitis and secondary to biologic treatment are currently rare and not predictable. Regular control of renal function and urinalysis during treatment with anti-TNF is mandatory. A concomitant treatment with Disease Modifying Anti Rheumatic Drugs or eventually a low dose of steroids may prevent the formation of anti-drug antibodies and could limit the renal damage related to this phenomenon.
format Online
Article
Text
id pubmed-7683916
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-76839162020-12-03 Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review Diena, Davide Priora, Marta Barreca, Antonella Parisi, Simone Colla, Loredana Biancone, Luigi Fusaro, Enrico Clin Med Insights Case Rep Case Report With the widespreading use of biologic drugs, reports of renal injury are increasing, most of which belong to the spectrum of secondary autoimmune syndromes. We present the case of a young man affected by Ankylosing Spondylitis, treated with tumor necrosis factor alpha inhibitors (Anti-TNF) that develop a peculiar renal damage: a coexistence of 2 glomerulonephritis due to different noxae, an IgA nephropaty with a Membranous nephropathy. The first one probably related to the rheumatologic disease, the second one related to Anti-TNF. Despite the underlying mechanisms, the renal involvement both related to Ankylosing Spondylitis and secondary to biologic treatment are currently rare and not predictable. Regular control of renal function and urinalysis during treatment with anti-TNF is mandatory. A concomitant treatment with Disease Modifying Anti Rheumatic Drugs or eventually a low dose of steroids may prevent the formation of anti-drug antibodies and could limit the renal damage related to this phenomenon. SAGE Publications 2020-11-20 /pmc/articles/PMC7683916/ /pubmed/33281463 http://dx.doi.org/10.1177/1179547620974672 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Diena, Davide
Priora, Marta
Barreca, Antonella
Parisi, Simone
Colla, Loredana
Biancone, Luigi
Fusaro, Enrico
Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review
title Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review
title_full Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review
title_fullStr Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review
title_full_unstemmed Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review
title_short Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review
title_sort double glomerulonephritis in a patient with ankylosing spondylitis treated with biologic agent: extrarticolar involvement or anti-tumor necrosis factor alpha injury? a case-based review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683916/
https://www.ncbi.nlm.nih.gov/pubmed/33281463
http://dx.doi.org/10.1177/1179547620974672
work_keys_str_mv AT dienadavide doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview
AT prioramarta doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview
AT barrecaantonella doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview
AT parisisimone doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview
AT collaloredana doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview
AT bianconeluigi doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview
AT fusaroenrico doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview